Insider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Buys 18,000 Shares of Stock

Knight Therapeutics Inc. (TSE:GUDGet Rating) insider Long Zone Holdings Inc. purchased 18,000 shares of the company’s stock in a transaction that occurred on Thursday, June 16th. The stock was bought at an average price of C$5.18 per share, with a total value of C$93,240.00. Following the purchase, the insider now owns 21,723,933 shares of the company’s stock, valued at approximately C$112,529,972.94.

Long Zone Holdings Inc. also recently made the following trade(s):

  • On Wednesday, May 18th, Long Zone Holdings Inc. acquired 20,000 shares of Knight Therapeutics stock. The stock was acquired at an average cost of C$5.17 per share, with a total value of C$103,400.00.

Shares of GUD traded down C$0.01 during midday trading on Friday, hitting C$5.15. 30,808 shares of the stock traded hands, compared to its average volume of 217,153. Knight Therapeutics Inc. has a 1-year low of C$5.01 and a 1-year high of C$5.74. The firm has a market capitalization of C$593.74 million and a PE ratio of -93.82. The company has a debt-to-equity ratio of 5.64, a quick ratio of 2.05 and a current ratio of 2.73. The business’s 50 day moving average price is C$5.31 and its two-hundred day moving average price is C$5.35.

Knight Therapeutics (TSE:GUDGet Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported C($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.04) by C$0.02. The company had revenue of C$63.81 million for the quarter, compared to the consensus estimate of C$52.80 million. As a group, equities research analysts forecast that Knight Therapeutics Inc. will post -0.02 EPS for the current fiscal year.

A number of equities analysts have commented on GUD shares. National Bank Financial decreased their price objective on shares of Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating for the company in a report on Friday, March 25th. National Bankshares decreased their price objective on shares of Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating for the company in a report on Friday, March 25th. Raymond James set a C$7.50 price objective on shares of Knight Therapeutics and gave the stock an “outperform” rating in a report on Friday, April 1st. Bloom Burton reaffirmed a “buy” rating and issued a C$6.70 price objective on shares of Knight Therapeutics in a report on Monday, March 28th. Finally, Stifel Nicolaus downgraded shares of Knight Therapeutics to a “hold” rating and set a C$5.30 price objective for the company. in a report on Thursday, March 24th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Knight Therapeutics has a consensus rating of “Buy” and a consensus target price of C$7.00.

About Knight Therapeutics (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

Featured Articles

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Want More Great Investing Ideas?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.